Allergan and Valeant unable to agree… even on a date

Valeant and investor

William Ackman have obtained a three-day trial to begin on October 6 in Delaware. The objective: to have the special meeting of Allergan shareholders moved up to mid-November from the December 18 date (see August 28, 2014 news clip).

 

At the meeting, shareholders will decide the fate of directors who oppose the hostile takeover bid by Valeant and Pershing Square.

 

Valeant and Ackman believe that Allergan chose the December 18 date to give it time to find an alternative deal. They argue that Allergan had no intention of calling the special meeting, an argument that Judge Andre Bouchard accepted in his decision.

 

Allergan continues to maintain that the December 18 date was chosen to give the court in California time to render its verdict in the lawsuit against Pershing Square, Ackman’s hedge fund, for insider trading.

 

Pershing Square secretly began accumulating Allergan shares in February 2014. It disclosed its nearly 10% stake on April 21. The next day, Valeant and Pershing Square announced their hostile takeover bid. Allergan’s shares were pushed higher and the value of Pershing Square’s stake in the company rose to $1 billion.

 

If Pershing Square loses its case, it will not be allowed to vote at Allergan’s special meeting, which is why it wants the meeting date bumped up. Stay tuned…

 

Source: http://www.reuters.com/assets/print?aid=USKBN0GR1RT20140827

Featured Posts

MIDO 2023: Visitor Registration Now Open

Starting now, show goers can reserve their spot at the 2023 edition of MIDO

Learn More

FYidoctors Named Among Canada’s Top Growing Companies in Latest Report on Business Ranking

Diversified healthcare organization has grown to include 375 clinics across Canada

Read more

Bausch + Lomb Will Present Scientific Data and Analyses During World Cornea Congress

One Podium and Two Poster Presentations Will Highlight Pre-Clinical and Clinical Data for Investigational Treatment NOV03, as well as Data from Company’s Unique ARMOR Surveillance Study

Read more

Transitions and OAC Now Accepting Applications for the 2022 Students of Vision Scholarship Program

This year students will be asked to discuss the importance on diversity and multicultural efforts in eye care

Read more

Travel Yukon and Enchroma Help People With Colourblindness See the Northern Lights

Travel Yukon and EnChroma came together to make the show-stopping northern lights more accessible than ever before for the colourblind, and provided one Canadian with the chance to see this natural phenomenon in full colour for the first time.

Read more

MIDO 2023: Visitor Registration Now Open

Starting now, show goers can reserve their spot at the 2023 edition of MIDO

Learn More

FYidoctors Named Among Canada’s Top Growing Companies in Latest Report on Business Ranking

Diversified healthcare organization has grown to include 375 clinics across Canada

Read More

Bausch + Lomb Will Present Scientific Data and Analyses During World Cornea Congress

One Podium and Two Poster Presentations Will Highlight Pre-Clinical and Clinical Data for Investigational Treatment NOV03, as well as Data from Company’s Unique ARMOR Surveillance Study

Read More

Transitions and OAC Now Accepting Applications for the 2022 Students of Vision Scholarship Program

This year students will be asked to discuss the importance on diversity and multicultural efforts in eye care

Read More

Travel Yukon and Enchroma Help People With Colourblindness See the Northern Lights

Travel Yukon and EnChroma came together to make the show-stopping northern lights more accessible than ever before for the colourblind, and provided one Canadian with the chance to see this natural phenomenon in full colour for the first time.

Read More

MIDO 2023: Visitor Registration Now Open

Starting now, show goers can reserve their spot at the 2023 edition of MIDO

Learn More

FYidoctors Named Among Canada’s Top Growing Companies in Latest Report on Business Ranking

Diversified healthcare organization has grown to include 375 clinics across Canada

Read more

Bausch + Lomb Will Present Scientific Data and Analyses During World Cornea Congress

One Podium and Two Poster Presentations Will Highlight Pre-Clinical and Clinical Data for Investigational Treatment NOV03, as well as Data from Company’s Unique ARMOR Surveillance Study

Read more

Transitions and OAC Now Accepting Applications for the 2022 Students of Vision Scholarship Program

This year students will be asked to discuss the importance on diversity and multicultural efforts in eye care

Read more

Travel Yukon and Enchroma Help People With Colourblindness See the Northern Lights

Travel Yukon and EnChroma came together to make the show-stopping northern lights more accessible than ever before for the colourblind, and provided one Canadian with the chance to see this natural phenomenon in full colour for the first time.

Read more

MIDO 2023: Visitor Registration Now Open

Starting now, show goers can reserve their spot at the 2023 edition of MIDO

Learn More

FYidoctors Named Among Canada’s Top Growing Companies in Latest Report on Business Ranking

Diversified healthcare organization has grown to include 375 clinics across Canada

Read more

Bausch + Lomb Will Present Scientific Data and Analyses During World Cornea Congress

One Podium and Two Poster Presentations Will Highlight Pre-Clinical and Clinical Data for Investigational Treatment NOV03, as well as Data from Company’s Unique ARMOR Surveillance Study

Read more

Transitions and OAC Now Accepting Applications for the 2022 Students of Vision Scholarship Program

This year students will be asked to discuss the importance on diversity and multicultural efforts in eye care

Read more

Travel Yukon and Enchroma Help People With Colourblindness See the Northern Lights

Travel Yukon and EnChroma came together to make the show-stopping northern lights more accessible than ever before for the colourblind, and provided one Canadian with the chance to see this natural phenomenon in full colour for the first time.

Read more